A SIMPLE KEY FOR MKENA UNVEILED

CDER’s new proposal to withdraw the accelerated approval of Makena (HPC) was dependent upon a large randomized trial that failed to verify the advantage of this drug to newborns or lessen the potential risk of PTB. In making the decision to suggest Makena’s withdrawal, CDER also reviewed outcomes from prior experiments of progestins (HPC and